Side-by-side comparison of AI visibility scores, market position, and capabilities
Augmedics makes the xvision Spine System, the first FDA-cleared AR headset for spine surgery; completed 10,000th AR-guided surgery in April 2025; launched next-gen X2 headset with FDA 510(k) clearance.
Augmedics is a medical device and augmented reality company that develops surgical navigation technology for spine procedures. Founded in 2014 and headquartered in Chicago, Augmedics pioneered the application of see-through augmented reality in the operating room with its flagship xvision Spine System — the first FDA-cleared AR navigation device for spinal surgery in the United States. The system allows surgeons to visualize a patient''s anatomy in real time as if they have x-ray vision, overlaying CT-derived 3D models onto their direct view of the surgical field without looking away to a separate monitor.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.